PureTech Health contract revenues surge, cuts costs as portfolio strategy evolves
Biotherapeutics firm PureTech Health Plc said on Thursday that it had made "meaningful progress" across its portfolio in the first half of 2025, with contract revenues soaring throughout the period.
Puretech said contract revenues had surged 542.7% to $1.85m in the six months ended 30 June, primarily due to the recognition of royalty revenue from sales of its Cobenfy asset, while general and administrative expenses decreased by 10% to $24.9m, driven by workforce reductions. Total operating expenses for the first six months of the year were $49.8m, versus $66.7m at the same time a year earlier.
The FTSE 250-listed group highlighted that it was currently in a strong financial position, with $319.6m in PureTech level cash, cash equivalents, and short-term investments after the completion of the sale of its remaining stake in Vor, generating gross cash proceeds of approximately $2.8m.
Looking ahead, Puretech expects to see a significant reduction in operational expenses in FY26 as support for its Celea and Gallop units transitions to their respective founded entities.
Interim chief executive Robert Lyne said: "We entered 2025 with significant momentum, and our progress in the first half of the year further underscores the strength and breadth of our portfolio and model.
"Looking ahead, our approach to capital allocation will be guided by an efficient use of cash and prioritising spend that is truly value accretive to shareholders. Practically, this means optimising spend on current and any new programs to reach key inflexion points, after which programs can be advanced through Founded Entities or other structures with dedicated operational capacity and external financing."
As of 0815 BST, Puretech shares were down 0.45% at 133.40p.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
